Related Experiment Videos
Gefitinib-related gene signature in bladder cancer cells identified by a cDNA microarray
Ryo Inoue1, Hideyasu Matsuyama, Seiji Yano
1Department of Urology, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan.
Background:
The aim of this study was to identify key genes linked to the molecular action of gefitinib, a promising anticancer agent on human bladder cancer cell lines.
Materials And Methods:
cDNA microarrays were used to profile feature genes in 5637 and T24 cells before and after treatment with gefitinib. PCR-based direct sequencing and Western blot analysis were performed to examine the mutation status and protein levels of EGFR in the cell lines.
Results:
Gefitinib significantly inhibited the proliferation of 5637 cells, while showing little inhibitory effect on T24 cells. Theses effects were independent of the mutation status and protein levels of EGFR. cDNA microarray analysis identified 15 feature genes classified as a cell cycle, apoptotic pathway and transcription. Notably, levels of expression of the cell invasion-related genes, YY1 and E-cadherin, were increased in 5637 cells sensitive to gefitinib.
Conclusion:
Unique genes involved in the action of gefitinib were identified. Particularly, the upregulation of YY1 and E-cadherin may account for the efficacy of gefitinib in bladder cancer.
Insights
Gefitinib effectively targets bladder cancer cells by upregulating YY1 and E-cadherin, crucial for cell invasion. This study identifies key genes involved in gefitinib
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gefitinib is an anticancer agent with potential against human bladder cancer.
- Understanding its molecular targets is crucial for optimizing treatment.
Purpose of the Study:
- To identify key genes mediating gefitinib's anticancer effects in human bladder cancer cell lines.
- To investigate the role of EGFR in gefitinib's action.
Main Methods:
- cDNA microarrays were employed to profile gene expression in 5637 and T24 bladder cancer cells before and after gefitinib treatment.
- EGFR mutation status and protein levels were assessed using PCR and Western blot analysis.
Main Results:
- Gefitinib significantly inhibited 5637 cell proliferation but had minimal effect on T24 cells, independent of EGFR status.
- Microarray analysis revealed 15 differentially expressed genes related to cell cycle, apoptosis, and transcription.
- Upregulation of cell invasion-related genes YY1 and E-cadherin was observed in gefitinib-sensitive 5637 cells.
Conclusions:
- Key genes involved in gefitinib's mechanism of action in bladder cancer were identified.
- The upregulation of YY1 and E-cadherin may contribute to gefitinib's efficacy in bladder cancer treatment.